Inogen Inc (INGN)
NASDAQ:INGN
INGN Stock Chart & Stats
$6.21
$0.43(4.59%)
At close: 4:00 PM EST
$6.21
$0.43(4.59%)
Day’s Range― - ―
52-Week Range$5.34 - $9.13
Previous CloseN/A
Volume110.44K
Average Volume (3M)255.79K
Market Cap
$175.65M
Enterprise Value$86.40M
Total Cash (Recent Filing)$119.58M
Total Debt (Recent Filing)$17.48M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Apr 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding27,232,350
10 Day Avg. Volume238,525
30 Day Avg. Volume255,786
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-8.46
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.52
Enterprise Value/Ebitda-21.05
Forecast
1Y Price Target
$12.67Price Target Upside104.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$368.90M
Bulls Say, Bears Say
Bulls Say
Guidance And Analyst SupportCompany reiterated guidance for positive adjusted EBITDA and an analyst maintained a Buy rating despite the revenue shortfall, reinforcing expectations of profitability resilience.
Product Pipeline ExpansionAnalyst highlights new product launches, including a stationary oxygen concentrator and a CPAP mask family, as potential drivers of revenue growth and market share gains.
Profitability ImprovementAdjusted operating profitability improved, signaling stronger earnings quality that can support margin expansion.
Bears Say
Order Timing And Sales ImpactOrder delays and the shifting of several large customer orders into a later reporting period weakened sales performance and hurt reported results.
Segment Demand WeaknessUS sales, international sales, and rental revenue all came in below analyst estimates, indicating broader demand softness across markets and service lines.
Weaker Revenue GuidanceCompany's revenue guidance was lower than analyst consensus, reducing growth expectations for the business.
Inogen News
INGN FAQ
What was Inogen Inc’s price range in the past 12 months?
Inogen Inc lowest stock price was $5.34 and its highest was $9.13 in the past 12 months.
What is Inogen Inc’s market cap?
Inogen Inc’s market cap is $175.65M.
When is Inogen Inc’s upcoming earnings report date?
Inogen Inc’s upcoming earnings report date is Apr 30, 2026 which is in 15 days.
How were Inogen Inc’s earnings last quarter?
Inogen Inc released its earnings results on Feb 24, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.097.
Is Inogen Inc overvalued?
According to Wall Street analysts Inogen Inc’s price is currently Undervalued.
Does Inogen Inc pay dividends?
Inogen Inc does not currently pay dividends.
What is Inogen Inc’s EPS estimate?
Inogen Inc’s EPS estimate is -0.28.
How many shares outstanding does Inogen Inc have?
Inogen Inc has 27,232,350 shares outstanding.
What happened to Inogen Inc’s price movement after its last earnings report?
Inogen Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went up 2.911%.
Which hedge fund is a major shareholder of Inogen Inc?
Currently, no hedge funds are holding shares in INGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (104.03% Upside)
$12.67 (104.03% Upside)
Blogger Sentiment
Bullish
INGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 33.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.38%
12-Months-Change
Fundamentals
Return on Equity
-11.56%
Trailing 12-Months
Asset Growth
0.82%
Trailing 12-Months
Company Description
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
INGN Company Deck
INGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear operational and strategic turnaround: mid-single-digit revenue growth, >20% unit growth, strong international momentum, return to adjusted EBITDA profitability for the year, a strengthened balance sheet with no debt and a $30M buyback authorization, and meaningful product diversification with early traction for new launches. Headwinds remain — notably U.S. sales and rental declines, gross margin compression from channel mix, timing shifts of large orders into H1 2026, and an ongoing GAAP net loss — but management provided guidance for continued adjusted EBITDA positivity, 2026 revenue growth (mid-single digits to ~6% at midpoint) and longer-term targets (high single-digit growth and ≥10% adjusted EBITDA in 3–5 years). Overall, the positive operational progress, profitability inflection, cash position and portfolio expansion outweigh the near-term channel and timing challenges.View all INGN earnings summariesINGN Stock 12 Month Forecast
Average Price Target
$12.67
▲(104.03% Upside)
Technical Analysis
Ownership Overview
2.86% Insiders
17.64% Mutual Funds
18.07% Other Institutional Investors
52.54% Public Companies and
Individual Investors